ADArik Drucker

Arik Drucker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arik Drucker has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Akram Alwithenani

    Affiliations Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada, Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Makkah, Makkah, Saudi Arabia

    1 shared publication
  • Daniel French

    Affiliation Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

    1 shared publication
  • Daniel Rayson

    Affiliation Division of Medical Oncology, Department of Medicine, Dalhousie University and Nova Scotia Health Authority, Halifax, Nova Scotia, Canada

    1 shared publication
  • Devanand M. Pinto

    Affiliation Human Health Therapeutics Research Centre, National Research Council of Canada, Halifax, Nova Scotia, Canada

    1 shared publication
  • Drew Bethune

    Affiliation Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada

    1 shared publication
  • Evelyn M. Teh

    Affiliation Human Health Therapeutics Research Centre, National Research Council of Canada, Halifax, Nova Scotia, Canada

    1 shared publication

Latest Publications

  • Open Access

    Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients

    by Arik Drucker, Evelyn M. Teh, Ripsik Kostyleva, Daniel Rayson, Susan Douglas, Devanand M. Pinto

    The isolation and analysis of circulating tumor cells (CTC) has the potential to provide minimally invasive diagnostic, prognostic and predictive information. Widespread clinical implementation of CTC analysis has been hampered by a lack of comparative investigation between different analytic methodologies in clinically relevant settings. The objective of this study was to evaluate four different CTC isolation techniques–those that rely on surface antigen expression (EpCAM or CD45 using DynaBeads® or EasySep™ systems) or the biophysical properties (RosetteSep™ or ScreenCell®) of CTCs. These were evaluated using cultured cells in order to calculate isolation efficiency at various levels including; inter-assay and inter-operator variability, protocol complexity and turn-around time. All four techniques were adequate at levels above 100 cells/mL which is commonly used for the evaluation of new isolation techniques. Only the RosetteSep™ and ScreenCell® techniques were found to provide adequate sensitivity at a level of 10 cells/mL. These techniques were then applied to the isolation and analysis of circulating tumor cells blood drawn from metastatic breast cancer patients where CTCs were detected in 54% (15/28) of MBC patients using the RosetteSep™ and 75% (6/8) with ScreenCell®. Overall, the ScreenCell® method had better sensitivity.


  • Open Access

    Molecular profiling of non-small cell lung cancer

    by Marika L. Forsythe, Akram Alwithenani, Drew Bethune, Mathieu Castonguay, Arik Drucker, Gordon Flowerdew, Daniel French, John Fris, Wenda Greer, Harry Henteleff, et al.

    Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide more efficient treatment options as they target the individual’s genetic makeup. The goal of this study was to identify the frequency of causal genetic mutations across a variety of lung cancer subtypes in the earlier stages. 833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK. A SNaPshot assay was used for point mutations and fragment analysis searched for insertions and deletions. ALK was evaluated by IHC +/- FISH. Statistical analysis was performed to determine correlations between molecular and clinical/pathological patient data. None of the tested variants were identified in most (66.15%) of cases. The observed frequencies among the total samples vs. only the adenocarcinoma cases were notable different, with the highest frequency being the KRAS mutation (24.49% vs. 35.55%), followed by EGFR (6.96% vs. 10.23%), PIK3CA (1.20% vs. 0.9%), BRAF (1.08% vs. 1.62%), ALK (0.12% vs. 0.18%), while the lowest was the HER2 mutation (0% for both). The statistical analysis yielded correlations between presence of a mutation with gender, cancer type, vascular invasion and smoking history. The outcome of this study will provide data that helps stratify patient prognosis and supports development of more precise treatments, resulting in improved outcomes for future lung cancer patients.